12:00 AM
May 08, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Maxamine histamine dihydrochloride: Phase III

In MAXM's 305-patient U.S. Phase III trial, the combination of Maxamine plus IL-2 met one of two primary end points of a significant increase in survival duration compared to IL-2 alone. In the overall population, median survival of the Maxamine group was 272 days compared to 245 days for IL-2 patients, a difference that was not statistically significant. However, the primary...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >